Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$34.78 USD
-2.77 (-7.38%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $34.75 -0.03 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CLDX 34.78 -2.77(-7.38%)
Will CLDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
Acadia Healthcare (ACHC) Beats Q2 Earnings and Revenue Estimates
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Other News for CLDX
Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Celldex (CLDX)
Celldex: Latest Urticaria Data Gives Market Jitters - I'm On Sidelines
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Celldex selloff on anaphylaxis concerns overdone, says TD Cowen